NASDAQ · BCYC
Healthcare · Biotechnology
$3.66
Down-$0.16 (-4.19%)
Updated Oct 31, 2026, 3:32 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BCYC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BCYC closed at $3.66 after 21 trading sessions, up 8.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.75 | $3.80 | $3.60 | $3.66 | 348.59K |
| Oct 29, 2026 | $3.92 | $4.135 | $3.705 | $3.82 | 598.17K |
| Oct 28, 2026 | $3.76 | $3.89 | $3.71 | $3.88 | 436.24K |
| Oct 27, 2026 | $3.66 | $3.84 | $3.61 | $3.78 | 486.23K |
| Oct 26, 2026 | $3.56 | $3.69 | $3.53 | $3.65 | 525.96K |
| Oct 23, 2026 | $3.64 | $3.64 | $3.415 | $3.55 | 346.81K |
| Oct 22, 2026 | $3.56 | $3.64 | $3.525 | $3.64 | 276.24K |
| Oct 21, 2026 | $3.62 | $3.7969 | $3.56 | $3.57 | 406.4K |
| Oct 20, 2026 | $3.53 | $3.71 | $3.52 | $3.60 | 488.21K |
| Oct 19, 2026 | $3.45 | $3.64 | $3.41 | $3.535 | 692.06K |
| Oct 16, 2026 | $3.58 | $3.60 | $3.42 | $3.46 | 565.6K |
| Oct 15, 2026 | $3.51 | $3.64 | $3.50 | $3.60 | 411.54K |
| Oct 14, 2026 | $3.63 | $3.755 | $3.50 | $3.51 | 439.36K |
| Oct 13, 2026 | $3.81 | $3.88 | $3.63 | $3.63 | 456.96K |
| Oct 12, 2026 | $3.89 | $3.91 | $3.785 | $3.80 | 233.48K |
| Oct 9, 2026 | $3.81 | $3.92 | $3.775 | $3.89 | 300.62K |
| Oct 8, 2026 | $3.71 | $3.81 | $3.6201 | $3.81 | 338.68K |
| Oct 7, 2026 | $3.75 | $3.805 | $3.68 | $3.73 | 479.63K |
| Oct 6, 2026 | $4.02 | $4.025 | $3.735 | $3.79 | 620.68K |
| Oct 5, 2026 | $3.62 | $4.0386 | $3.61 | $4.01 | 1.85M |
| Oct 2, 2026 | $3.65 | $3.695 | $3.3301 | $3.38 | 728.67K |
The latest Smart Investors Daily articles mentioning BCYC.
Company
Market Activity
Research & News
BCYC research
Company profile and research snapshot.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Needham | Buy | — |
| Apr 8, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 18, 2026 | Oppenheimer | Outperform | — |
| Mar 18, 2026 | RBC Capital | Sector Perform | — |
| Mar 18, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Aug 4, 2026
Bicycle Therapeutics deprioritized zelenectide pevedotin after mixed progress in urothelial cancer. Find out why BCYC stock is downgraded to a hold.
Benzinga · Jul 30, 2026
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.
Benzinga · Jul 30, 2026
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.59) by 22.03 percent. This is a 36.84 percent increase over losses of $(1.14) per
Yahoo · Jun 2, 2026
European equities traded in the US as American depositary receipts were tracking higher late Tuesday
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCYC.
